Oxyview offers cost savings for the entire global oxygen industry. "It has been 90 days since the 36-month cap on oxygen equipment rental went into effect in the USA. Most providers have found a way to stay in business; although the industry is only faced with the initial challenge associated with revenue reduction and lower reimbursement. Oxyview will play a small role in a huge and growing industry by eliminating unnecessary service calls to the home oxygen patient, and easily diagnosing equipment malfunction that could lead to malpractice suits. Oxyview stands alone in the in-line gravity independent flow-meter market, with potential sales of $30M annually, and savings in the industry of 10 times that amount. One Oxyview costs less than a single service call," Stated Scott Sand, CEO and Chairman of Ingen Technologies.

Trustcash Announces Gross Revenues (Unaudited) Double for the Quarter End September 30

ATLANTA, GA, Oct 07, 2009 (MARKETWIRE via COMTEX) -- TRUSTCASH HOLDINGS, INC. ("TRUSTCASH") (PINKSHEETS: TCHH) today confirms gross revenue (unaudited) for three month period ending September 30, 2009 has increased by approximately 101% compared to the quarter ended June 30, 2009.
Specifically gross revenue (unaudited) increased to Four Hundred and Twenty Eight Thousand Seven Hundred dollars ($428,700) for the three month period ended September 30, 2009 compared to Two Hundred and Thirteen Thousand Two Hundred and Seven dollars ($213,207) for the quarter ended June 30, 2009.

Trustcash Management stated, "Our increase in revenue is a result of the launch of our virtual check out terminal and continued acceptance and use of the Trustcash merchant check out system generally. We continue to execute on our business plan and are preparing our financial statements to disclose to our shareholders. We expect our growth to continue."

About Trustcash

Through its Trustcash brand and website (Trustcash 2.0 ::: Anonymous. Secure. Private.), Trustcash is a pioneer of anonymous payment systems for the internet. Trustcash developed a business based on the sale of a virtual stored value card that can be used by consumers to make secure and anonymous purchases on the internet. The company markets its Trustcash(TM) payment card, which is sold in denominations ranging from $10 to $200 online.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological changes and uncertainties related to the development of Trustcash's business model. The actual results Trustcash may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.



Contact:
Trustcash Holdings, Inc.
Shareholder Communications
Email Contact: Email Contact
1-800-975-5196


SOURCE: Trustcash



CONTACT: Marketwire - Contact Form

Copyright 2009 Marketwire, Inc., All rights reserved.
-0-

SUBJECT CODE: Computers and Software:Internet
Financial Services:Commercial and Investment Banking
Retail:E-Commerce
Financial Services:Retail Banking
Financial Services:Personal Finance

this is looking to be a real winner. its starting to prove its self vol is up and keeps rising with poss news at close today

iv been on and off with them for a while now and they have been good to me but With them receving that proposal to reduce prodution and material cost by 50% along with sales going up to give them a foothold in the market im back on again

IGNT

is in a buyers market right now its a low risk with the potential to make a quick profit and with the possibility of news breaking later in the day it should start to move with a very good chance to heat up. bb's adding, next week will be big imo.

Ingen Brings Aboard Leading OEM Partner for Australia


Medical Industries Australia Pty LTD Signs OEM Contract

YUCAIPA, Calif., Oct 23, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that Medical Industries Australia has signed an OEM contract with Ingen.
Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services, and provides high quality products and services to the Australian healthcare sector and has been supplying distributors and resellers, public and private hospitals, government departments, private clinics, aged care facilities and medical surgeries for more than 20 years.

In Australia, under the national Medicare health scheme, all interstitial lung disease and COPD patients who require oxygen therapy, are provided with a 5 liter/min oxygen concentrator at no cost, this includes a free Oxygen tubing & nasal cannula each month. State Government funded, the concentrators and consumables suppliers are selected by tender, usually on a 3+1 year arrangement.

In the case of new or innovative devices, such as Ingen's Oxyview Nasal Cannula, they fall outside the state tender and can be offered to public government-funded hospitals for trial and evaluation and if accepted, purchased by the various respiratory departments to be used by their patients. Approximately 1,000 COPD patients, each day, occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it's due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis.

"I look forward to working with Angus Taylor, CEO of Medical Industries Australia. He has already mentioned strong interest from local acute public hospitals in Sydney. We will commence product shipments upon completion of our ISO Certification and CE Mark expected in late December-2009," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Medical Industries Australia > Home

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, GlobeNewswire - Press Release Distribution - EDGAR Filings - Video News Releases

SOURCE: Ingen Technologies, Inc.


By Staff

CONTACT: CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
Ingen Technologies,Inc. - Home

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
-0-

INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: MEDICAL
Business Contracts

Hey all ignt had great volume on fri closeing @ 118.4 mil and up 11.7%!!! Rsi line is bullish @51.48 and mac d line is even with the signal line and has been since july!!. Next resistace is .0047. Imo this stock is going to have great volume and price increases throughout the week. This stock is on my radar and im loooking to make a profit!!!!

ignt started to move friday and with news that came out friday and today that should get this moving ignt is a good quick investment , should get hot through the week with more poss news at close today

Pinnacle Digest: Looking For Shareholder Opinions On Ingen Technologies' Latest News

Oct 26, 2009 (M2 PRESSWIRE via COMTEX) -- Pinnacle Digest | Your Investment Growth Resource | Pinnacle Digest is a performance-driven online financial magazine and social network with a proven track record. After Friday's news from Ingen Technologies, Inc. (Pink Sheets:IGNT) announcing that Medical Industries Australia has signed an OEM contract with Ingen, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all Ingen shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Join The Ingen Investor Discussion Here: Ingen Technologies Inc | Pinnacle Digest

Join PinnacleDigest.com to

Find out if Ingen makes it as a Pinnacle Featured Company,

Chat with other shareholders invested in Ingen,

Explain to our investor community what differentiates this company,

Connect with investors and professionals in the equity markets,

Meet the thousands of investors who have already become members of the Pinnacle community.

PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.

PinnacleDigest.com has no vested interest in the company mentioned herein. The company mentioned in this release has not compensated PinnacleDigest.com in any form to disseminate this release.

This source of information is from an unbiased perspective. If you wish to become a member of Pinnacle Digest | Your Investment Growth Resource | Pinnacle Digest you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.

All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Pinnacledigest.com undertakes no obligation to update such statements.

CONTACT: Pinnacle Digest WWW: Pinnacle Digest | Your Investment Growth Resource | Pinnacle Digest

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.




(C)1994-2009 M2 COMMUNICATIONS
-0-

Ingen CEO Live Radio Interview Today With The Money Channel
Increased Sales, Margins and Profits Bring Bright Future for Shareholders

Press Release
Source: Ingen Technologies, Inc.
On 12:38 pm EDT, Tuesday October 27, 2009
Buzz up! Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Oct. 27, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the CEO, Scott Sand, discussed increased profits, margins and sales at 11:34am eastern daylight time today on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.00 0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
"The company sales for first quarter had increased more than a 100 times compared to last year due to the acceptance of the product by the home oxygen patients and respiratory medical market. Margins of sales were slightly better than 63%. The future of this company for any investor, compared to other companies in the market place, is strong and steady," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



The company introduced a new revolutionary product into the medical market this past June-2009, called the Oxyview Nasal Cannula. Oxyview, the World's First Patient In-Line Oxygen Flow-Meter, and Oxyview Nasal Cannula, the World's First Cannula with a built-in oxygen flow meter is another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients who require home oxygen therapy or supplemental oxygen.



Welcome



Medco Forum - About Us



American College of Chest Physicians



Welcome to the COPD Digest!



Senior Living : Retirement : Elderly Health : Today's Senior Magazine



MEDICA 2009 - Messe Düsseldorf North America



index



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.






Contact:
Ingen Technologies, Inc.Jeff Morgan909-790-7180 Ingen Technologies,Inc. - Home